Please login to the form below

Not currently logged in
Email:
Password:

Former Sanofi chairman joins Pertinax Pharma

Nigel Brooksby will drive the commercialisation of the company as chairman

Pertinax Pharma has appointed Nigel Brooksby as its new chairman, a role that will see him help drive the commercialisation of the company by assisting in corporate strategic and business developments.

During his 38-year career in the pharmaceutical industry, Brooksby has served in roles such from medical sales representative to chairman.

He has held senior appointments in Wellcome - now GSK, Pfizer and as chairman and MD at Sanofi UK and Ireland and as a member of the Sanofi Executive Committee in Europe and America.

Michele Barbour, founder and chief scientific officer, Pertinax Pharma, said: “We are delighted that Nigel has chosen to join our board.

“His unparalleled experience in the pharmaceutical and related industries, his long established industry connections and his experience with early stage biomedical companies make him the ideal individual for the tasks at hand.

“We look forward to Nigel playing a pivotal role in Pertinax Pharma’s continued development as bring the benefits of our patented and commercialised Pertinax technology to the healthcare sector.”

24th November 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
foxandcat.online

some pressure is helpful but too much of the wrong sort quickly takes its toll. we help creatove agenices manage...

Latest intelligence

Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...